In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

A new drug, NXP800, shows promise in treating hormone therapy-resistant prostate cancer by targeting the Heat Shock Factor 1 (HSF1) pathway, which supports cancer cell growth.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

The drugs treat prostate, breast and blood cancers. About 80,000 people with Medicare Part D coverage used them in a one-year ...

but their optimal use—such as which drug or drug combinations should be used first to achieve the best outcomes from prostate cancer treatment—is still being worked out. Nevertheless ...

In severe cases, an enlarged prostate could lead to bladder or kidney problems if left untreated. The following items don’t cause BPH, but could make your symptoms worse, including: certain ...